More about

Ipilimumab

News
September 16, 2024
2 min read
Save

Nivolumab plus ipilimumab offers ‘potential for cure’ in advanced melanoma

Nivolumab plus ipilimumab offers ‘potential for cure’ in advanced melanoma

The addition of nivolumab to ipilimumab conferred a long-term OS benefit for patients with advanced melanoma, according to study results presented at ESMO Congress.

News
June 02, 2024
3 min read
Save

Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma

Neoadjuvant immunotherapy ‘the new standard’ for resectable stage III melanoma

CHICAGO — Individuals with resectable stage III melanoma derived significant EFS benefits with neoadjuvant immunotherapy compared with standard treatment, results from a randomized phase 3 trial presented at ASCO Annual Meeting showed.

News
June 02, 2024
3 min read
Save

‘Practice-changing data’ support first-line immunotherapy combination in colorectal cancer

‘Practice-changing data’ support first-line immunotherapy combination in colorectal cancer

CHICAGO — Combination immunotherapy significantly improved outcomes vs. first-line chemotherapy for patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer, according to study results.

News
June 01, 2024
3 min read
Save

Targeted induction before immunotherapy shows limited benefit in advanced melanoma

Targeted induction before immunotherapy shows limited benefit in advanced melanoma

CHICAGO — Sequencing encorafenib plus binimetinib with nivolumab and ipilimumab did not delay disease progression in adults with advanced BRAF-mutated melanoma, results from a randomized phase 2 trial showed.

News
May 13, 2024
1 min read
Save

Phase 3 trial of nivolumab for advanced lung cancer misses primary endpoint

Phase 3 trial of nivolumab for advanced lung cancer misses primary endpoint

A randomized phase 3 trial that evaluated nivolumab with concurrent chemoradiotherapy for certain patients with advanced lung cancer failed to meet its primary endpoint, according to the agent’s manufacturer.

News
March 21, 2024
1 min read
Save

Immunotherapy combination improves survival in advanced liver cancer

Immunotherapy combination improves survival in advanced liver cancer

The addition of nivolumab to ipilimumab significantly improved OS among adults with previously untreated advanced hepatocellular carcinoma, according to a release by the agent’s manufacturer.

News
March 20, 2024
2 min watch
Save

VIDEO: Notable PFS improvement from nivolumab plus ipilimumab for colorectal cancer

VIDEO: Notable PFS improvement from nivolumab plus ipilimumab for colorectal cancer

In this video, Afsaneh Barzi, MD, PhD, discusses the results of the CheckMate 8HW study.

News
March 13, 2024
2 min read
Save

Neoadjuvant immunotherapy may improve sarcoma outcomes

Neoadjuvant immunotherapy may improve sarcoma outcomes

A phase 2 trial conducted by researchers at The University of Texas MD Anderson Cancer Center demonstrated the safety and potential efficacy of neoadjuvant immunotherapy for patients with soft tissue sarcoma.

News
November 21, 2023
2 min read
Save

Trial eligibility linked to better outcomes after immunotherapy for renal cell carcinoma

Trial eligibility linked to better outcomes after immunotherapy for renal cell carcinoma

NASHVILLE, Tenn. — Patients with renal cell carcinoma who met eligibility criteria for pivotal phase 3 trials achieved significantly longer survival after combination immunotherapy than trial-ineligible patients, according to study results.

News
November 02, 2023
3 min read
Save

‘Tolerant fraction’ metric IDs those at risk for immunotherapy-related toxicity

‘Tolerant fraction’ metric IDs those at risk for immunotherapy-related toxicity

Researchers at UT Southwestern Medical Center have introduced a new metric that may be useful in predicting which patients are likely to develop immunotherapy toxicity.

View more